Skip to main content
SpringerLink
Log in

Analgetika

  • Chapter
  • First Online:
Book cover Arzneiverordnungs-Report 2019

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Andrade S, Bartels DB, Lange R, Sandford L, Gurwitz J (2016) Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther 41:459–477

    Article  CAS  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (1986) Bundesgesundheitsamt schränkt Anwendungsgebiet von Metamizol-haltigen Monopräparaten ein. Dtsch Arztebl 83:3267

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2007a) Empfehlungen zur Therapie von Tumorschmerzen. AVP-Sonderheft Therapieempfehlungen, 3. Auflage. http://www.akdae.de/35/10/66-Tumorschmerzen-2007-3Auflage.pdf

  • Arzneimittelkommission der deutschen Ärzteschaft (2007b) Leberschäden unter Flupirtin. Dtsch Arztebl 104:A3200

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2012) Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen. Dtsch Arztebl 109:A724–A725

    Google Scholar 

  • Bornemann-Cimenti H, Wejbora M, Szilagyi I, Sandner-Kiesling A (2013) Fentanyl zur Behandlung von tumorbedingten Durchbruchschmerzen. Dtsch Arztebl 110:271–277

    Google Scholar 

  • Boscarino JA, Rukstalis M, Hoffmann SN, Han JJ, Erlich PM, Gerhard GS, Steward WF (2010) Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:1776–1782

    Article  Google Scholar 

  • Brat GA, Agniel D, Beam A, Yorkgitis B, Bickel M, Homer M, Fox KP, Knecht DB, McMahill-Walraven CN, Palmer N, Kohane I (2018) Postsurgical prescriptions for opioid naïve patients and association with overdose and misuse: retrospective cohort study. Brit Med J 360:j5790

    Article  Google Scholar 

  • Budd K (1990) Experience with partial antagonists in the treatment of cancer pain. In: Doyle D (Hrsg) Opioids in the treatment of cancer pain. International congress and symposium series, Bd. 146. Royal Society of Medicine, S 51–54

    Google Scholar 

  • Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC (2014) Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane review. Spine 39:556–563

    Article  Google Scholar 

  • Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2005) Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94:825–834

    Article  CAS  Google Scholar 

  • Devulder J (2010) Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 24:867–881

    Article  CAS  Google Scholar 

  • Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D (2002) Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97:827–836

    Article  CAS  Google Scholar 

  • European Medicines Agency (2018) Widerruf des Schmerzmittels Flupirtin bestätigt. Weiterhin Fallberichte über schwere Leberschädigungen trotz vorheriger Anwendungsbeschränkungen. https://www.ema.europa.eu/en/medicines/human/referrals/flupirtine-containing-medicinal-products#overview-section

    Google Scholar 

  • Faria J, Barbosa J, Moreira R, Queirós O, Dinis-Oliveira RJ (2018) Comparative pharmacology and toxicology of tramadol and tapentalol. Eur J Pain 22:827–844

    Article  CAS  Google Scholar 

  • Frampton JE (2010) Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 70:1719–1743

    Article  CAS  Google Scholar 

  • Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589–1594

    Article  Google Scholar 

  • Garbe E, Jobski K, Schmid U (2012) Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 21:191–198

    Article  Google Scholar 

  • Hanks GW, De Conno F, Cherny N, Expert Working Group of the Research Network of the European Association for Palliative Care (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593

    Article  CAS  Google Scholar 

  • Jacox A, Carr DB, Payne R, Agency for Health Care Policy and Research (AHCPR) Pharmacological Management (1994) Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. AHCPR Publication, Bd. 94-0592. U.S. Department of Health and Human Services, Public Health Service, Rockville

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2012a) Oxycodon/Naloxon. Wirkstoff aktuell Ausgabe 6/2012. http://www.akdae.de/Arzneimitteltherapie/WA/Archiv/Oxycodon-Naloxon.pdf

  • Kassenärztliche Bundesvereinigung (2012b) Tapentadol. Wirkstoff aktuell Ausgabe 3/2012. http://www.akdae.de/Arzneimitteltherapie/WA/Archiv/Tapentadol.pdf

  • Kaye AD, Jones MR, Kaye AM, Ripoll JG, Galan V, Beakley BD, Calixto F, Bolden JL, Urman RD, Manchikanti L (2017) Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain Physician 20:93–109

    Article  Google Scholar 

  • Langford RM, Knaggs R, Farguhar-Smith P, Dickenson AH (2016) Is tapentalol different from classical opioids? A review of the evidence. Brit J Pain 10:217–221

    Article  Google Scholar 

  • Lauche R, Klose P, Radbruch R, Welsch P, Häuser W (2015) Opioids in chronic noncancer pain – are opioids superior to nonopioid analgesics? A systematic review and metaanalysis to efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four weeks duration. Schmerz 29:85–95

    Article  Google Scholar 

  • Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K (2009) A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13:56–64

    Article  CAS  Google Scholar 

  • Quigley C (2002) Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002 (1): CD003447

    Google Scholar 

  • Radbruch L, Elsner F (2005) Palliative Schmerztherapie, Cannabinoide. Internist 46:1105–1114

    Article  CAS  Google Scholar 

  • Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F (2006) Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 14:400–407

    Article  Google Scholar 

  • Schubert I, Ihle P, Sabatowski R (2013) Zunahme der Opioidverordnungen in Deutschland zwischen 2000 und 2011. Dtsch Arztebl 110:45–51

    Google Scholar 

  • Shah RR (2019) Metamizole (dipyrone)-induced agranulocytosis: Does the risk vary according to ethnicity? J Clin Pharm Ther 44:129–133

    Article  CAS  Google Scholar 

  • Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC (2008) Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 138:440–449

    Article  Google Scholar 

  • The Pain Society (2004) Recommendations for the appropriate use of opioids for persistent non-cancer pain. http://www.britishpainsociety.org/pdf/opioids_doc_2004.pdf (Erstellt: 03.2004) (A consensus statement prepared on behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists)

    Google Scholar 

  • Wiffen PJ, Derry S, Naessens K, Bell RF (2015) Oral tapentalol for cancer pain. Cochrane Database Syst Rev 2015: CD011460

    Google Scholar 

  • Wilcock A (2009) Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain 1001(2009):13

    Google Scholar 

  • World Health Organization (WHO) (1986) Cancer pain relief. World Health Organization Publications, Geneva

    Google Scholar 

  • World Health Organization (WHO) (1996) Cancer pain relief, 2. Aufl. World Health Organization Publications, Geneva

    Google Scholar 

  • Zhang WY, Po AL (1996) Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain – a metaanalysis. J Clin Pharm Ther 21:261–282

    Article  CAS  Google Scholar 

  • Zhang WY, Po AL (1997) Do codeine and caffeine enhance the analgesic effect of aspirin? A systematic overview. J Clin Pharm Ther 22:79–97

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Hamburg, Deutschland

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie der Universität Göttingen, Göttingen, Deutschland

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer H. Böger .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Köln, Nordrhein-Westfalen, Germany

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK, Berlin, Berlin, Germany

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Böger, R.H., Schmidt, G. (2019). Analgetika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2019. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59046-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59046-1_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59045-4

  • Online ISBN: 978-3-662-59046-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation